Table 1:
Clinical characteristics, and baseline comorbidities and anti-thrombotic therapy of the LAA occlusion population.
| N = 106 | ||
|---|---|---|
| Gender | ||
| Male | N (%) | 77 (72.6) |
| Age (yrs) | Median (min-max) | 74 (46–87) |
 75 yrs |
N (%) | 49 (46.2) |
| Dialytic age (yrs) | Median (min-max) | 2.21 (0.47–7.33) |
 3 yrs |
N (%) | 42 (39.6) |
| BMI (kg/m2) | Median (Q1–Q3) | 25 (22–28) |
| Missing data (%) | 20 (18.9) | |
| Current smoking | ||
| Yes | N (%) | 10 (9.6) |
| Missing data (%) | 2 (1.9) | |
| CHA2DS2VASc | Median (Q1–Q3) | 4 (3–5) |
| HASBLED | Median (Q1–Q3) | 4 (4–5) |
| Atrial fibrillation | ||
| Paroxysmal | N (%) | 38 (35.8) |
| Persistent | N (%) | 18 (17.0) |
| Permanent | N (%) | 50 (47.2) |
| Comorbidities | ||
| Hypertension | N (%) | 95 (89.6) |
| Diabetes mellitus | N (%) | 40 (37.7) |
| Dyslipidemia | N (%) | 58 (54.7) |
| Peripheral artery disease | N (%) | 57 (53.8) |
| Ischaemic heart disease | N (%) | 46 (43.4) |
| Heart failure | N (%) | 36 (34.0) |
| Chronic pulmonary disease | N (%) | 22 (20.8) |
| Previous ischaemic stroke | N (%) | 11 (10.4) |
| Previous pulmonary thromboembolism | N (%) | 2 (1.9) |
| Previous major bleeding | N (%) | 66 (62.3) |
| Echocardiography | ||
| Atrium dilatation | N (%) | 88 (85.4) |
| N of missing data | 3 | |
| Left ventricular ejection fraction <50% | N (%) | 20 (19.0) |
| N of missing data | 1 | |
| Left ventricular hypertrophy | N (%) | 52 (57.8) |
| N of missing data (%) | 16 | |
| Baseline antithrombotic therapy | ||
| Antiplatelet | N (%) | 68 (64.2) |
| Heparin | N (%) | 33 (31.1) |
| Warfarin | N (%) | 31 (29.2) |
| Baseline antiarrhythmic therapy | ||
| Beta-blockers | N (%) | 59 (56.0) |
| Amiodarone | N (%) | 9 (8.5) |
| Sotalol | N (%) | 2 (1.9) |
| Other antiarrhythmic drugs | N (%) | 5 (4.7) |
BMI, body mass index; LAA, left atrial appendage.